Teva Pharmaceutical Industries Limited (LON:0LER)
London
· Delayed Price · Currency is GBP · Price in USD | Market Cap | 29.30B |
| Revenue (ttm) | 12.82B |
| Net Income (ttm) | 1.05B |
| Shares Out | n/a |
| EPS (ttm) | 0.90 |
| PE Ratio | 27.97 |
| Forward PE | 12.55 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 7,872 |
| Average Volume | 16,708 |
| Open | 33.50 |
| Previous Close | 33.64 |
| Day's Range | 33.04 - 33.90 |
| 52-Week Range | 12.50 - 37.30 |
| Beta | 0.72 |
| RSI | 46.47 |
| Earnings Date | May 6, 2026 |
About LON:0LER
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The com... [Read more]
News
Here's Why I Won't Touch Teva Pharmaceutical With a 10‑Foot Pole
Teva Pharmaceutical Industries is a large manufacturer of generic drugs. The company is working to expand into more complex generics and to develop its own drugs.
Allspring Smid Cap Growth Fund Q4 2025 Top Contributors And Detractors
Investor attention turned more intensely to the scale, timing, and funding of AI-related capital commitments, prompting renewed debate about whether expectations were running ahead of eventual monetiz...
Teva to Present at the Upcoming Investor Conferences in March
PARSIPPANY, N.J. and TEL AVIV, Israel, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will ...
FDA Accepts Teva's New Long-Acting Schizophrenia Treatment Application
Teva Pharmaceuticals Industries Ltd (NYSE: TEVA) on Friday announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for olanzapine extended-release injec...
Teva (TEVA) Advances Schizophrenia Treatment with FDA Application
Teva (TEVA) Advances Schizophrenia Treatment with FDA Application
Teva, Medincell granted FDA review for long-acting antipsychotic
FDA Accepts NDA For Teva And Medincell's Olanzapine LAI In Schizophrenia Treatment
(RTTNews) - Teva Pharmaceuticals, the U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), together with Medincell, announced that the U.S. Food and Drug Administration (FDA) has accepted its...
Teva (TEVA) Gains FDA Nod for Schizophrenia Treatment Application
Teva (TEVA) Gains FDA Nod for Schizophrenia Treatment Application
U.S. Food and Drug Administration (FDA) Accepts Teva's New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults
PARSIPPANY, N.J. and TEL AVIV, Israel and PARIS, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Medincell (E...
Price Over Earnings Overview: Teva Pharmaceutical Indus
In the current market session, Teva Pharmaceutical Indus Inc. (NYSE: TEVA) stock price is at $34.97, after a 2.32% drop. However, over the past month, the company's stock went up by 5.42% , and in th...
Allspring Mid Cap Growth Fund Q4 2025 Performance Insights, Portfolio Drivers & Decisions
Allspring Mid Cap Growth Fund Q4 2025 Performance Insights, Portfolio Drivers & Decisions
Corcept Therapeutics Stock Plunges As Court Clears Teva Generic
Corcept Therapeutics shares plunged Thursday morning after a federal appeals court upheld a ruling that Teva Pharmaceuticals' proposed generic does not infringe two Korlym-related patents. ... Full st...
Corcept falls as appeals court sides with Teva in Korlym patent dispute
Corcept Therapeutics (CORT) stock plunged after an appeals court backed Teva (TEVA) in a patent dispute over the company's lead drug Korlym. Read more here.
Truist Securities Raises Price Target for TEVA, Maintains Buy Rating | TEVA Stock News
Truist Securities Raises Price Target for TEVA, Maintains Buy Rating | TEVA Stock News
Teva Pharmaceutical Industries Limited (TEVA) Discusses Duvakitug IBD Phase 2b Maintenance Top-Line Results - Slideshow
2026-02-17. The following slide deck was published by Teva Pharmaceutical Industries Limited in conjunction with this event.
Sanofi, Teva Report Positive Phase 2b Results For Duvakitug
(RTTNews) - Sanofi SA (SNY) and Teva Pharmaceutical Industries Ltd. (TEVA) reported on Tuesday, positive long-term extension data from the phase 2b RELIEVE UCCD study of duvakitug in ulcerative coliti...
Teva, Sanofi's Phase 2b Trial Of Duvakitug Shows Durable Efficacy In UC & Crohn's
(RTTNews) - Teva Pharmaceutical Industries Ltd. (TEVA) and Sanofi (SNY) will hold an investor call and webcast today to highlight new Phase 2b maintenance data for Duvakitug. The investigational thera...
Teva Pharmaceutical's New Study Shows Lasting Relief For Inflammatory Bowel Disease Patients
Teva Pharmaceutical Industries Limited (NYSE: TEVA) shares are higher during Tuesday’s premarket session as the company is discussing positive results from its recent clinical study. Positive Data Fr...
Teva Pharmaceutical's New Study Shows Lasting Relief For Inflammatory Bowel Disease Patients
Teva and Sanofi SA (NASDAQ: SNY) released positive results on Tuesday from the RELIEVE UCCD long-term extension study of duvakitug, an investigational human monoclonal antibody targeting TL1A.
Teva (TEVA) and Sanofi Report Positive Results for Duvakitug in UC and Crohn's
Teva (TEVA) and Sanofi Report Positive Results for Duvakitug in UC and Crohn's
Teva, Sanofi report durable phase 2b efficacy for duvakitug in ulcerative colitis, Crohn’s disease
Teva and Sanofi's duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn's disease
In the RELIEVE UCCD LTE phase 2b study, duvakitug showed robust, durable efficacy for an additional 44 weeks in UC and CD patients who had responded after 14 weeks of induction Duvakitug was well tole...
Press Release: Sanofi and Teva's duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn's disease
Sanofi and Teva's duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn's disease In the RELIEVE UCCD LTE phase 2b study, duvakitug sh...
Teva and Sanofi's duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn's disease
Teva will hold an investor call and live webcast today, Tuesday, February 17, 2026, at 8:00 a.m. ET to discuss these data.